WC
UTHR icon

Westerkirk Capital’s United Therapeutics UTHR Stock Holding History

Westerkirk Capital’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$318K Hold
586
– – 0.03% 178
2026
Q1 		$347K Hold
586
– – 0.04% 163
2025
Q4 		$286K Buy
586
+91
+18% +$42.4K 0.03% 185
2025
Q3 		$208K Hold
495
– – 0.02% 226
2025
Q2 		$142K Buy
+495
New +$148K 0.02% 220

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Westerkirk Capital's UTHR Position: Q2 2026 in Review

Westerkirk Capital held its United Therapeutics (UTHR) position steady in Q2 2026 at 586 shares worth $318K. The position accounts for 0.03% of the portfolio, ranked #178.

Westerkirk Capital first reported a position in UTHR in Q2 2025 and has held it in 5 quarters since. The position peaked at $347K in Q1 2026. 882 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Westerkirk Capital held 586 shares of United Therapeutics worth $318K as of Q2 2026.
  • Westerkirk Capital left its United Therapeutics share count unchanged in Q2 2026.
  • United Therapeutics made up 0.03% of Westerkirk Capital's portfolio in Q2 2026, its #178 holding.
  • Westerkirk Capital first reported a position in United Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Westerkirk Capital's United Therapeutics position peaked at $347K in Q1 2026.
  • 882 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Westerkirk Capital's 13F filing for Q2 2026, filed 10 Aug 2026.